Intellia Therapeutics earnings date
Intellia Therapeutics (38I) Q2 2026 Earnings Report
DE:38I Q2 2026 EPS Results
- Actual EPS
- -EUR 0.72
- Consensus EPS
- -EUR 0.72
- Beat/Miss
- Missed by -EUR 0.00
- One Year Ago EPS
- -EUR 0.89
DE:38I Q2 2026 Revenue Results
- Actual Revenue
- EUR 6.92M
- Expected Revenue
- EUR 11.73M
- Beat/Miss
- Missed by -EUR 4.81M
- YoY Revenue Growth
- -46.23%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 08/06/2026
- Time
- Before Open
- Conference Call
- Thursday, August 6, 2026
Intellia Therapeutics's next earnings date is estimated for February 25, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
The call conveyed strong, concrete clinical progress — most notably the unequivocal Phase III success for lonvo‑z (87% attack reduction, 62% attack‑free and therapy‑free, favorable safety) and compelling nex‑z biological data (≈90% TTR knockdown, rapid and durable) — alongside active regulatory and commercial preparations. Financially, the company strengthened its cash position with a ~$195M financing and maintains a runway into at least 2028, although collaboration revenue declined and G&A rose as commercial build‑out continues. The primary concern is a nex‑z liver enzyme safety signal and the identification of an HLA C*05:01 subgroup (~12% of samples) associated with higher Grade 3+ transaminase events; the company has implemented mitigation, added HLA typing to protocols, and is engaging regulators. Overall, the positive clinical milestones and clear mitigation plan for the safety finding outweigh the operational and financial headwinds discussed.
Intellia said it expects FDA acceptance of the lonvo‑z BLA by year‑end and is preparing for a potential U.S. launch in H1 2027 (pre‑commercial hires complete); it reported $628.4M cash, cash equivalents and marketable securities as of June 30, 2026 (after ~ $195M net equity financing in April) and believes this funding should carry the company at least into 2028 (conservative, excludes product revenue); Q2 metrics included collaboration revenue $7.7M, R&D $82.6M (stock‑comp $9.4M), G&A $37.8M (stock‑comp $8.6M) and net loss $106.6M; clinical guidance highlighted HAELO topline that showed an 87% reduction in mean monthly attacks vs placebo, 62% of patients attack‑ and therapy‑free, and a 23‑point improvement in angioedema QoL over 6 months (vs a 6‑point meaningful change), while nex‑z dosing resumed in Q2, MAGNITUDE has enrolled >650 patients with a blinded event rate within internal projections and MAGNITUDE‑2 enrollment expected to complete later this year; safety work sequenced >600 samples, found HLA C*05:01 in ~12% of patients and linked it to the highest transaminase elevations (Grade 4 events <1% overall), prompting HLA typing and mitigation measures across ongoing trials, and Phase I nex‑z showed ~90% mean TTR reduction with mean serum TTR <20 µg/mL within 1 month.
- HAELO Phase III (lonvo-z) — Strong EfficacyPhase III HAELO achieved statistical significance for the primary and all key secondary endpoints: an 87% reduction in mean monthly attacks versus placebo during the 6-month primary period; 62% of patients were entirely attack-free and therapy-free; and a 23‑point improvement in total angioedema quality‑of‑life score from baseline (vs. 6 points considered clinically meaningful). All patients in the lonvo‑z arm experienced attack rate reductions for weeks 5–28.
- HAELO Safety and One‑Time Therapy ProfileFavorable safety/tolerability observed in lonvo‑z: most common TEAEs were infusion‑related reactions, headache and fatigue; all TEAEs Grade 1–2 and no serious adverse events reported in the lonvo‑z arm as of data cutoff. Majority of patients remained off long‑term prophylaxis during the 6‑month efficacy period after a single dose.
- Regulatory and Commercial Readiness for lonvo‑zRolling BLA submission to FDA underway following HAELO topline; company expects to announce FDA acceptance of the BLA by year‑end and is preparing for a potential U.S. launch in H1 2027. Pre‑commercial efforts advanced (hiring of field medical, reimbursement and strategic accounts teams; payer outreach, treatment center readiness, distribution planning and disease awareness initiatives).
- nex‑z: Potent, Rapid and Durable TTR KnockdownPhase I data show mean TTR reduction of ~90% and mean serum TTR <20 µg/mL (about one‑third of the absolute level seen with a leading chronic silencer). Knockdown achieved rapidly (within 1 month) and was highly consistent across patients; intra‑patient TTR control has been maintained long‑term following the one‑time nex‑z treatment.
- MAGNITUDE Enrollment and Event AccrualMAGNITUDE (nex‑z Phase III) has enrolled well over 650 patients and resumed enrollment and dosing in Q2 after resolving clinical holds; the blinded event rate remains within the company’s internal projection range, and the trial’s primary endpoint is event‑based (not time‑bound).
- Genomic Insight Enables Precision Mitigation for nex‑zBlinded analysis of >600 patient samples identified a statistically significant association between HLA allele C*05:01 and higher rates of Grade 3+ transaminase elevations, providing a mechanistic explanation for the signal and enabling pre‑screening (HLA typing) and mitigation measures to be implemented across Phase III protocols and informed consents.
- Strengthened Balance Sheet and RunwayCompleted an equity financing in April yielding approximately $195 million in net proceeds. Cash, cash equivalents and marketable securities were $628.4 million as of June 30, 2026 versus $605.1 million on Dec 31, 2025 (increase of $23.3M, ~3.9%). Company believes cash runway extends at least into 2028 (conservative, excludes potential product revenues).
- Operational Discipline in R&D SpendR&D expense decreased to $82.6 million in Q2 2026 from $97.0 million in the prior‑year quarter (a reduction of ~$14.4M, ~14.9%), driven by lower external costs related to lonvo‑z and nex‑z and reduced stock‑based compensation (partially offset by higher employee‑related expenses).
DE:38I Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 25, 2027 | 2026 (Q4) | -0.72- | -0.75 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | -0.72-0.82 | -0.83 | 1.09% (+0.01) | |
| Aug 06, 2026 | 2026 (Q2) | -0.72-0.72 | -0.89 | 18.37% (+0.16) | |
| May 11, 2026 | 2026 (Q1) | -0.82-0.73 | -0.99 | 26.36% (+0.26) | |
| Feb 26, 2026 | 2025 (Q4) | -0.86-0.75 | -1.15 | 34.65% (+0.40) | |
| Nov 06, 2025 | 2025 (Q3) | -0.91-0.83 | -1.21 | 31.34% (+0.38) | |
| Aug 07, 2025 | 2025 (Q2) | -0.92-0.89 | -1.37 | 35.53% (+0.49) | |
| May 08, 2025 | 2025 (Q1) | -1.16-0.99 | -1.01 | 1.79% (+0.02) | |
| Feb 27, 2025 | 2024 (Q4) | -1.20-1.15 | -1.32 | 13.01% (+0.17) | |
| Nov 07, 2024 | 2024 (Q3) | -1.26-1.21 | -1.25 | 2.90% (+0.04) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

